Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2143957 | 0.87 | LTA4H (0.51) | SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL430014 | 0.86 | POLB (0.53) | SIGMAR1KCNH2NPC1HTR2BPOLB | |
| SCHEMBL7554391 | 0.83 | SIGMAR1 (0.44) | SIGMAR1KCNH2NPC1KDM4EALDH1A1 | |
| SCHEMBL460928 | 0.82 | KDM4E (0.45) | SIGMAR1KCNH2KDM4EALDH1A1TSHR | |
| SCHEMBL460929 | 0.82 | SIGMAR1 (0.46) | SIGMAR1KCNH2NPC1KDM4EALDH1A1 | |
| SCHEMBL7554381 | 0.80 | SIGMAR1 (0.44) | SIGMAR1KCNH2NPC1KDM4EALDH1A1 | |
| SCHEMBL7554389 | 0.80 | SIGMAR1 (0.44) | SIGMAR1KCNH2NPC1KDM4EALDH1A1 | |
| SCHEMBL3118354 | 0.80 | GAA (0.48) | KDM4EALDH1A1POLBTSHR | |
| SCHEMBL25263718 | 0.80 | SIGMAR1 (0.48) | SIGMAR1KCNH2KDM4EALDH1A1HTR2B | |
| SCHEMBL445617 | 0.80 | HRH2 (0.51) | SIGMAR1NPC1KDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| EP-2247591-A1 | PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | SIGMAR1 2387/4885KCNH2 3325/4885NPC1 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.